Nature Medicine May 12, 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Louis J. Aronne et al.

Bottom Line

The ATTAIN-MAINTAIN trial demonstrated that switching from injectable incretin therapies to once-daily oral orforglipron effectively maintained the majority of weight loss achieved during initial treatment.

Key Findings

1. Participants transitioning from maximum tolerated doses of semaglutide to orforglipron maintained all but 0.9 kg of their previously achieved weight loss after 52 weeks.

2. Participants switching from tirzepatide to orforglipron maintained all but 5.0 kg of their prior weight loss after 52 weeks.

3. In the prior-tirzepatide cohort, participants maintained a mean 74.7% of their body weight reduction with orforglipron compared with 49.2% on placebo.

4. In the prior-semaglutide cohort, participants maintained a mean 79.3% of their body weight reduction with orforglipron compared with 37.6% on placebo.

5. The most common adverse events were gastrointestinal, including nausea (18.8% in the orforglipron group vs. 4.1% in the placebo group) and constipation (13.1% vs. 4.1%).

Study Design

Design

Phase 3b RCT

Double-Blind

Sample

376

Patients

Duration

52 wk

Median

Setting

Multicenter

Population Adults with obesity who had completed the SURMOUNT-5 head-to-head study, achieving at least 5% weight loss on either tirzepatide (n=205) or semaglutide (n=171), and had reached a weight plateau.

Intervention Once-daily oral orforglipron, escalated to a maximum tolerated dose (up to 36 mg) for 52 weeks.

Comparator Placebo

Outcome Proportion of weight loss from the initial SURMOUNT-5 study maintained at 52 weeks.

Study Limitations

• The 52-week duration limits the assessment of long-term weight maintenance and safety beyond one year.

• The study compared orforglipron to a placebo rather than performing a head-to-head comparison with continued injectable therapy (semaglutide or tirzepatide).

• The patient population was drawn exclusively from participants who had successfully completed the SURMOUNT-5 trial, which may limit generalizability to other real-world populations.

Clinical Significance

ATTAIN-MAINTAIN provides robust clinical evidence that a non-peptide oral GLP-1 receptor agonist can serve as an effective maintenance therapy following aggressive initial weight loss with injectable biologics. This step-down approach presents a more convenient, injection-free, and potentially more scalable solution for the chronic management of obesity, addressing adherence barriers related to long-term injections and refrigeration.

Historical Context

Obesity care shifted dramatically with the advent of highly efficacious injectable incretins (GLP-1 and dual GLP-1/GIP agonists such as semaglutide and tirzepatide). However, maintaining weight loss remains a profound challenge; discontinuation of treatment typically results in rapid weight regain. The ATTAIN clinical trial program evaluated orforglipron, the first daily oral small-molecule GLP-1RA, to provide an accessible and practical maintenance solution to sustain cardiometabolic benefits.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the molecular structure and mechanism of action of orforglipron differ from traditional injectable GLP-1 receptor agonists like semaglutide, and why does this allow it to be administered orally without requiring co-formulation with absorption enhancers like SNAC?

Key Response

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike peptide-based GLP-1 RAs which require absorption enhancers like SNAC to buffer stomach acid and allow transcellular absorption under strict fasting conditions, orforglipron's small-molecule nature protects it from proteolytic degradation in the GI tract, allowing standard oral administration independent of food intake.

Resident

A patient who achieved 15 percent body weight reduction on weekly subcutaneous semaglutide wishes to switch to daily oral orforglipron due to injection fatigue. Based on the ATTAIN-MAINTAIN trial, what should you counsel them regarding weight trajectory and side effect management during the transition?

Key Response

Residents must manage the practical transition between medications. Counseling should emphasize that orforglipron effectively maintains the majority of weight lost, though minor fluctuations may occur. The patient must be warned about a potential transient recurrence of gastrointestinal side effects like nausea during the switch and dose-titration phase, and advised on standard daily oral adherence.

Fellow

In the context of the ATTAIN-MAINTAIN trial, what does the successful maintenance of weight loss with a non-peptide GLP-1 agonist imply about the 'incretin plateau' and receptor desensitization commonly observed after 12 to 18 months of continuous injectable peptide therapy?

Key Response

Fellows should understand receptor dynamics. The ability to maintain peak weight loss with a different molecular ligand implies that the well-documented weight plateau is likely driven by the establishment of a new metabolic and counter-regulatory homeostatic set point rather than irreversible GLP-1 receptor down-regulation or tachyphylaxis, confirming continuous receptor agonism remains effective long-term.

Attending

Given the findings of the ATTAIN-MAINTAIN trial, how could the strategic use of an oral small-molecule maintenance therapy fundamentally transform our chronic care model for obesity and address global supply chain constraints?

Key Response

Attendings focus on systems-based practice. Using highly effective injectables for the initial 'induction' phase of weight loss and transitioning to an easily synthesized, cheaper oral agent for 'maintenance' introduces a step-down therapy model to obesity medicine. This approach could optimize healthcare resource allocation, improve long-term patient adherence, and mitigate critical shortages of injectable incretins.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The ATTAIN-MAINTAIN trial evaluated maintenance of weight loss after switching therapies. Methodologically, how does the choice between a treatment-policy estimand and an efficacy (hypothetical) estimand impact the handling of missing data and the interpretation of weight regain when participants discontinue the oral medication?

Key Response

PhDs must rigorously evaluate estimands. In maintenance trials, dropouts often rapidly regain weight. A treatment-policy estimand includes this regain (reflecting real-world effectiveness), whereas an efficacy estimand censors data after discontinuation to isolate the biological maintenance effect of the drug. Balancing these approaches is critical to avoiding biased estimates of the drug's long-term utility.

Journal Editor

As a peer reviewer, what critical flags would you raise regarding the potential for functional unblinding in this trial, given the distinct gastrointestinal side-effect profiles of initiating a new oral incretin, and how might this influence behavioral confounders?

Key Response

Editors look for subtle biases. Switching from an established injectable to a new oral medication often causes a flare in GI side effects that can functionally unblind participants to their treatment arm. Unblinded participants may alter their diet or lifestyle (the Hawthorne effect), thereby artificially inflating the maintenance effect in the active arm compared to placebo.

Guideline Committee

Current obesity management guidelines treat pharmacotherapy primarily as continuous monotherapy. How should the ATTAIN-MAINTAIN evidence be integrated into future iterations of guidelines to formalize an 'induction and maintenance' framework, and what strength of recommendation does this trial provide?

Key Response

Guidelines currently lack explicit protocols for switching therapy to maintain weight loss. This Phase 3b RCT provides strong, high-quality evidence to update guidelines with a formal 'step-down' or transition pathway. Guidelines should offer a strong recommendation for transitioning patients to oral small molecules if they face injection fatigue or access barriers, thereby individualizing long-term chronic obesity management.

Clinical Landscape

Noteworthy Related Trials

2021

STEP 4 Trial

n = 803 · JAMA

Tested

Subcutaneous semaglutide 2.4 mg weekly

Population

Adults with overweight or obesity without diabetes

Comparator

Placebo (withdrawal)

Endpoint

Percentage change in body weight from week 20 to week 68

Key result: Continued semaglutide yielded an additional 7.9% weight loss, whereas switching to placebo resulted in a 6.9% weight regain.

2023

SURMOUNT-4 Trial

n = 783 · JAMA

Tested

Subcutaneous tirzepatide maximum tolerated dose

Population

Adults with obesity or overweight without diabetes

Comparator

Placebo (withdrawal)

Endpoint

Mean percent change in body weight from week 36 to week 88

Key result: Patients continuing tirzepatide achieved an additional 5.5% weight loss, while those switched to placebo regained 14% of their body weight.

2023

OASIS 1 Trial

n = 667 · Lancet

Tested

Oral semaglutide 50 mg daily

Population

Adults with overweight or obesity without diabetes

Comparator

Placebo

Endpoint

Percentage change in body weight from baseline to week 68

Key result: Oral semaglutide 50 mg led to a superior 15.1% reduction in body weight compared to 2.4% with placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis